Ro24-7429

Research use only, not for human use.

Ro24-7429 is an effective and orally active antagonist of HIV-1 transactivator protein Tat and an inhibitor of a runt-related transcription factor 1.

Ro24-7429 is an effective and orally active antagonist of HIV-1 transactivator protein Tat and an inhibitor of a runt-related transcription factor 1. Ro24-7429 has anti-HIV, antifibrotic, and anti-inflammatory effects.(In Vitro):Ro24-7429 (50-200 μM; 24-72 hours) strongly inhibits the proliferation of A549 and HLF cells in a dose-dependent manner. Ro24-7429 treatment (75 μM) significantly reduces TNF-α-induced up-regulation of RUNX1 mRNA by 50% at 48 hours. Ro 24-7429 (1-25 μM) induces apoptosis and inhibits antigen-induced lymphocyte proliferation. Ro 24-7429 (0.1 μM, 1 μM, 5 μM; 3 days) induces apoptosis of cultured PBMCs in a dose-dependent manner.(In Vivo):Ro24-7429 (17.5-70 mg/kg; i.p.) curbs expression of fibrosis markers in injured mouse lungs. Ro24-7429 robustly ameliorates lung fibrosis and inflammation in the Bleomycin-induced pulmonary fibrosis mouse model.

Apoptosis Analysis Cell Line:Peripheral blood mononuclear cells (PBMCs) Concentration:0.1 μM, 1 μM, 5 μM Incubation Time:3 days Result:Induced a dose-dependent increase in apoptosis of cultured PBMCs.

Animal Model:C57BL/6J male and female mice (aged 6 to 8 weeks) induced by Bleomycin Dosage:17.5 mg/kg, 35 mg/kg, and 70 mg/kg Administration:i.p.; daily; for 14 or 21 days Result:Ameliorated lung fibrosis and inflammation in the Bleomycin-induced PF mouse model.

Ro 24-7429 | Ro-24-7429 | Ro 247429

Microbiology/Virology

HIV

——

——

——

139339-45-0

272.74

C14H13ClN4

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (229.16 mM)

CNC1=Nc2ccc(Cl)cc2C(=NC1)c1ccc[nH]1

——

(-20℃)

With Ice Pack

≥ 2 years